Source disclosure: January 15, 2026
3-D Matrix,Ltd. [7777.T]
TOKYO, Jan 15 (Pulse News Wire) – 3-D Matrix,ltd. (7777.T) announced the initiation of a physician-led specific clinical study evaluating PureStat, its absorbable hemostatic agent, for post-thyroidectomy bleeding at the Shizuoka Cancer Center.
The study aims to assess the efficacy and safety of PureStat in cases where conventional methods fail to achieve adequate hemostasis after thyroid removal surgery. Thyroid surgeries often result in seepage bleeding due to the gland's attachment to the trachea via strong ligaments, posing risks such as severe complications and vocal cord dysfunction.
Current treatments like cauterization and gauze compression are less than ideal, necessitating safer and more efficient alternatives. In addition to assessing hemostatic effectiveness, the study will evaluate the incidence of postoperative vocal cord function impairment and drainage duration.
3-D Matrix stated that this research does not impact the company’s full-year performance or medium-term business plan.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing